At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
Efavirenz +1 moredrug
Likely dose
Quizartinib 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Parallel Drug Interaction Study to Evaluate the Effect of a CYP3A Moderate Inducer Efavirenz on the Pharmacokinetics of Quizartinib in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Efavirenz and Quizartinib for Healthy Subjects and 3 related conditions. Completed, enrolled 32 participants across 1 site.
Detailed Summary
This drug-drug interaction (DDI) study has been designed to investigate the effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of quizartinib and its major circulating active metabolite AC886.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Subjects, Drug-drug Interaction, Pharmacokinetics, Quizartinib
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartAug 2020
Primary CompletionOct 2020
TodayJul 2026
First PostedJul 7, 2020
Enrollment StartAug 19, 2020
Primary CompletionOct 14, 2020
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 6.0 years ago
Interventions
Efavirenzdrug
Single oral dose, 600-mg tablet
Quizartinibdrug
Single oral dose, 60 mg (2 x 30 mg) tablets